Literature DB >> 6306165

Diazepam potentiates the effect of neuroleptics on behavioural activity as well as dopamine and norepinephrine turnover: Do benzodiazepines have antipsychotic potency?

R L Singhal, R B Rastogi, Y D Lapierre.   

Abstract

A single injection of diazepam (10 mg/kg, s.c.), haloperidol (2 mg/kg, i.p.) or chlorpromazine (10 mg/kg, i.p.) decreased the ambulatory as well as sniffing behaviour of rats. These behavioural responses were further decreased when diazepam was administered concurrently with the neuroleptic. Acute haloperidol or chlorpromazine treatment increased striatal dopamine as well as cerebro-cortical norepinephrine turnover. In contrast, diazepam diminished the release of both of these catecholamines. When diazepam was administered together with haloperidol or chlorpromazine, a further decrease particularly in dopamine release was seen in striatum. This effect of diazepam on norepinephrine and dopamine turnover persisted even after 21 days of daily treatment, Similarly, the sedative effect of diazepam elicited in the form of depressed locomotor activity was also apparent after long-term administration of this benzodiazepine. However, chronic administration of neuroleptics enhanced the spontaneous locomotor activity and sniffing behaviour by about 25%. Furthermore, repeated neuroleptic treatment decreased the synthesis and turnover of dopamine and norepinephrine. This was reflected in decreased tyrosine hydroxylase and homovanillic acid level in striatum as well as by low concentration of 3-methoxy-4-hydroxyphenylethylene glycol in the cerebral cortex. When diazepam was administered together with haloperidol or chlorpromazine for 21 days, behavioural activity remained elevated and was comparable to groups of rats receiving neuroleptics alone. The cocomitant injection of diazepam and neuroleptics for 21 days elicited a synergistic effect on decreased synthesis and release of dopamine as well as norepinephrine. These data provide neurochemical evidence for potentiation of the neuroleptic effects by a benzodiazepine.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6306165     DOI: 10.1007/bf01243272

Source DB:  PubMed          Journal:  J Neural Transm            Impact factor:   3.575


  36 in total

1.  Evidence for the role of brain norepinephrine and dopamine in "rebound" phenomenon seen during withdrawal after repeated exposure to benzodiazepines.

Authors:  R B Rastogi; Y D Lapierre; R L Singhal
Journal:  J Psychiatr Res       Date:  1977       Impact factor: 4.791

Review 2.  The possible involvement of GABA mechanisms in the action of benzodiazepines on central catecholamine neurons.

Authors:  K Fuxe; L F Agnati; P Bolme; T Hökfelt; P Lidbrink; A Ljungdahl; M Pérez de la Mora; S Ogren
Journal:  Adv Biochem Psychopharmacol       Date:  1975

Review 3.  Effects of benzodiazepines on central serotonergic mechanisms.

Authors:  L Stein; C D Wise; J D Belluzzi
Journal:  Adv Biochem Psychopharmacol       Date:  1975

4.  Does dopamine play a role in schizophrenia?

Authors:  A Carlsson
Journal:  Psychol Med       Date:  1977-11       Impact factor: 7.723

5.  Neuroleptic drug interactions with norepinephrine alpha receptor binding sites in rat brain.

Authors:  S J Peroutka; D C U'Prichard; D A Greenberg; S H Snyder
Journal:  Neuropharmacology       Date:  1977-09       Impact factor: 5.250

6.  The importance of the ascending dopaminergic systems to the extrapyramidal and mesolimbic brain areas for the cataleptic action of the neuroleptic and cholinergic agents.

Authors:  B Costall; R J Naylor
Journal:  Neuropharmacology       Date:  1974-05       Impact factor: 5.250

7.  Potentiation of phenothiazines by -methyltyrosine in treatment of chronic schizophrenia.

Authors:  A Carlsson; T Persson; B E Roos; J Wålinder
Journal:  J Neural Transm       Date:  1972       Impact factor: 3.575

8.  Dopamine agonists reverse the elevated 3H-neuroleptic binding in neuroleptic-pretreated rats.

Authors:  S J List; P Seeman
Journal:  Life Sci       Date:  1979-04-16       Impact factor: 5.037

9.  gamma-Aminobutyric acid (Gaba) and the dopamine hypothesis of schizophrenia.

Authors:  D P Van Kammen
Journal:  Am J Psychiatry       Date:  1977-02       Impact factor: 18.112

10.  High dose diazepam in schizophrenia.

Authors:  H Beckmann; S Haas
Journal:  Psychopharmacology (Berl)       Date:  1980       Impact factor: 4.530

View more
  4 in total

Review 1.  Pharmacological management of acute agitation.

Authors:  John Battaglia
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  Benzodiazepine receptors increase in post-mortem brain of chronic schizophrenics.

Authors:  Y Kiuchi; T Kobayashi; J Takeuchi; H Shimizu; H Ogata; M Toru
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1989

3.  Effects of acute lorazepam administration on aminergic activity in normal elderly subjects: relationship to performance effects and apolipoprotein genotype.

Authors:  Nunzio Pomara; Lisa M Willoughby; Audrey Hashim; Henry Sershen; John J Sidtis; Keith Wesnes; David J Greenblatt; Abel Lajtha
Journal:  Neurochem Res       Date:  2004-07       Impact factor: 3.996

4.  Enhanced efficacy and reduced side effects of diazepam by kava combination.

Authors:  Rasha A Tawfiq; Noha N Nassar; Wafaa I El-Eraky; Ezzeldein S El-Denshary
Journal:  J Adv Res       Date:  2013-08-22       Impact factor: 10.479

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.